May 6, 2022
Company name:Name of representative:

Inquiries:

FINDEX Inc
Teruo Aibara, President & CEO(Securities code: 3649; PRIMEMarket)
Atsushi Fujita, Director and Headof Administration(Telephone: +81-89-947-3388)

Strategic Alliance with Toyota Tsusho Corporation
At an extraordinary meeting of the Board of Directors held on May 6, 2022, the Company resolved to enter intoa strategic partnership agreement with Toyota Tsusho Corporation ((hereafter referred to as "Toyota Tsusho")regarding medical information system business and health tech business and entered into the agreement on thesame date.
1. Reason for AllianceWith our goal of "Toward better health and wellbeing of all people" we have delivered a lot of healthcareorganizations with integrated digital solutions, which realize their centralized management and effective
utilization of test data and document data. Also, leveraging our nurtured technology and trust, we, ourself,invented, developed, manufactured, and sold gaze analyzing perimeter which adopts a completely new testing
principle.
Towards better society, at such a momentous time, we are committed to improve the convenience and efficiencyof medical exam at healthcare organizations overseas, as well as early detection of optical diseases, andeducational activities in Japan, in collaboration with Toyota Tsusho, who has built up relationships of trust throughtheir wide variety of businesses around the world.

2. Area for Alliance
The Company and Toyota Tsusho will cooperate under an exclusive sales agreement mainly for the followingsolutions.
(i) Overseas sales of medical information solutions
As the geographical strategies, we will sell medical information platform, mainly our flagship product "Claio"(image filing system), to key healthcare organizations in India and the ASEAN region. We will establish a cordial
support system in collaboration with local medical system companies to ensure efficient and sustainable deliveryof our product and service. In June 2022, we will introduce Claio, on a trial basis, to Sakra World Hospital in India,
which Toyota Tsusho has its investment stake, and begin test operations.
With a population of over 1.3 billion, the healthcare market of India has an unprecedented scalability, and at thesame time, there remain a lot of issues that can be ameliorated by digitalization. Addressing challenges to solve
issues out there, we will contribute to the realization of a sustainable society by improving the quality of medicalcare and the efficiency of hospital management.
(ii) Introduction of "GAP-screener" (gaze analyzing perimeter/regulatory product) to health checkup facilities inJapan
GAP-screener", which was commercialized for optional use during health checkups, will be introduced todomestic health checkup facilities and multiphasic health screening facilities under Toyota Tsusho's sales strategy.
This product is our original invention, darkroom-free, objective optical testing device.
By permanently exhibiting this solution other than ophthalmology facilities, more convenient testing will beenabled, leading to the early detection of glaucoma. We will also utilize the visual field data obtained through thetest, for various possibilities in future research and development in the medical field, such as the establishment ofnew treatment methods.
1

3. Corporate Profile of Strategic Alliance Partner①

Corporate Name②
③Location (head office)President & CEO

④⑤
⑥
⑦

⑧⑨

Toyota Tsusho Corporation

9-8, Meieki 4-chome, Nakamura-ku, Nagoya
Ichiro KashitaniGeneral trading and business investment company, engaged in metal, parts
Businessand logistics, automotive, machinery, energy and project, chemical andelectronics, food and consumer services, etc.
Capital64,936 million yen
Establishment
July 1, 1948
TOYOTA MOTOR CORPORATION 21.69％
The Master Trust Bank of Japan, Ltd. (Trust Account) 13.56％
Major Shareholders
TOYOTA INDUSTRIES CORPORATION 11.18％(As of September 30, 2021)
Capital, human, transaction, related
Relationship with our GroupN/Aparties(JPY in 100 million）
Recent three-year performance and financial status
Fiscal year201920202021
Total asset
44,41445,45252,280Net asset
13,896
13,724
16,580Gross profit
6,384
6,398
6,076
Operating income
2,151
2,103
2,130
Income before tax
2,291
2,248
2,214
Net income
1,326
1,355
1,346
EPS (JPY)
376.89385.25382.56
DOE (JPY)
100
110
112

4. Schedule
Date of resolution at Board of Director：May 6, 2022
Date of alliance agreement：May 6, 2022
Date of the commencement of business：May 6, 2022

5. Outlook
The impact of this strategic alliance on our performance is currently under inspection, we believe that thisalliance will significantly contribute to our corporate value enhancement in the medium to long term. In a timely
manner, we will appropriately announce any matters that should be disclosed.

2